Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Conclusions: Entrectinib demonstrated significant anti-tumor activity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene rearrangement, indicating that entrectinib may be an effective therapy for tumors with NTRK gene rearrangements, including those with central nervous system metastases.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Brief Report Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | CT Scan | Genetics | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Pain | PET Scan | Study